trending Market Intelligence /marketintelligence/en/news-insights/trending/b8aueigqvnp0orzy2yuraq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Arena closes $405.7M common stock offering to fund clinical trials

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Arena closes $405.7M common stock offering to fund clinical trials

Arena Pharmaceuticals Inc. completed an underwritten public offering of its common shares, raising about $405.7 million in gross proceeds.

The San Diego-based biopharmaceutical company issued 9,775,000 common shares at $41.50 apiece. The total shares sold included 1,275,000 shares, which were issued as part of the full exercise of the underwriters' option to buy additional shares.

Arena Pharmaceuticals plans to use net proceeds to develop its clinical candidates, including phase 3 programs for etrasimod to treat ulcerative colitis and ralinepag for treating pulmonary arterial hypertension.

In addition, the company plans to use the net proceeds for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures.

Citigroup, Leerink Partners, Cantor Fitzgerald, Credit Suisse and RBC Capital Markets acted as joint book-running managers, while Guggenheim Securities and JMP Securities acted as co-managers for the offering.